Amylyx Pharmaceuticals (AMLX) Financials

$4.88 +0.09 (+1.94%)

As of 11:06 AM Eastern

Annual Income Statements for Amylyx Pharmaceuticals

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-302	49	-198
Consolidated Net Income / (Loss)	-302	49	-198
Net Income / (Loss) Continuing Operations	-302	49	-198
Total Pre-Tax Income	-302	54	-198
Total Operating Income	-315	39	-201
Total Gross Profit	81	355	19
Total Revenue	87	381	22
Operating Revenue	87	381	22
Total Cost of Revenue	5.95	25	2.99
Operating Cost of Revenue	5.95	25	2.99
Total Operating Expenses	396	317	221
Selling, General & Admin Expense	114	188	127
Research & Development Expense	140	128	93
Other Operating Expenses / (Income)	119	0.00	-
Restructuring Charge	23	0.00	-
Total Other Income / (Expense), net	13	15	3.74
Interest & Investment Income	14	16	4.29
Other Income / (Expense), net	-1.21	-0.66	-0.55
Income Tax Expense	-0.39	5.03	0.77
Basic Earnings per Share	($4.43)	$0.73	($3.39)
Weighted Average Basic Shares Outstanding	68.14M	67.23M	58.50M
Diluted Earnings per Share	($4.43)	$0.70	($3.39)
Weighted Average Diluted Shares Outstanding	68.14M	69.99M	58.50M
Weighted Average Basic & Diluted Shares Outstanding	88.60M	67.78M	66.72M

This table shows Amylyx Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-38	-73	-73	-119	4.73	21	22	1.57	-43	-54
Consolidated Net Income / (Loss)	-38	-73	-73	-119	4.73	21	22	1.57	-43	-54
Net Income / (Loss) Continuing Operations	-38	-73	-73	-119	4.73	21	22	1.57	-43	-54
Total Pre-Tax Income	-38	-73	-73	-119	6.48	22	24	1.40	-42	-54
Total Operating Income	-41	-76	-76	-122	1.93	19	20	-2.05	-45	-55
Total Gross Profit	-0.67	0.42	-1.03	83	99	97	93	66	19	0.17
Total Revenue	-0.67	0.42	-1.02	89	108	103	98	71	22	0.35
Operating Revenue	-0.67	0.42	-1.02	89	108	103	98	71	22	0.35
Total Operating Expenses	40	76	75	205	97	79	72	68	64	55
Selling, General & Admin Expense	17	18	22	58	52	49	43	44	41	30
Research & Development Expense	23	57	23	37	45	30	29	24	23	25
Total Other Income / (Expense), net	2.47	2.96	3.59	3.58	4.54	3.69	3.81	3.46	2.47	0.80
Interest & Investment Income	2.32	3.10	4.07	4.33	4.37	4.18	3.89	3.72	3.16	0.60
Other Income / (Expense), net	0.16	-0.14	-0.48	-0.75	0.17	-0.49	-0.08	-0.26	-0.69	0.20
Income Tax Expense	-0.64	0.00	0.00	0.24	1.75	1.52	1.93	-0.17	0.58	-0.13
Basic Earnings per Share	($0.54)	($1.07)	($1.07)	($1.75)	$0.07	$0.31	$0.33	$0.02	($0.61)	($0.92)
Weighted Average Basic Shares Outstanding	68.14M	68.09M	68.02M	67.85M	67.23M	67.41M	67.23M	66.72M	58.50M	58.53M
Diluted Earnings per Share	($0.54)	($1.07)	($1.07)	($1.75)	$0.07	$0.30	$0.31	$0.02	($0.61)	($0.92)
Weighted Average Diluted Shares Outstanding	68.14M	68.09M	68.02M	67.85M	69.99M	69.75M	70.13M	70.86M	58.50M	58.53M
Weighted Average Basic & Diluted Shares Outstanding	88.60M	68.55M	68.08M	68.01M	67.78M	67.52M	67.38M	67.18M	66.72M	66.26M

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-92	108	13
Net Cash From Operating Activities	-168	12	-180
Net Cash From Continuing Operating Activities	-168	12	-180
Net Income / (Loss) Continuing Operations	-302	49	-198
Consolidated Net Income / (Loss)	-302	49	-198
Depreciation Expense	0.90	1.09	0.49
Amortization Expense	-9.86	-9.94	-2.06
Non-Cash Adjustments To Reconcile Net Income	189	37	23
Changes in Operating Assets and Liabilities, net	-46	-66	-3.28
Net Cash From Investing Activities	76	92	-239
Net Cash From Continuing Investing Activities	76	92	-239
Purchase of Property, Plant & Equipment	-0.16	-1.24	-2.53
Acquisitions	-36	0.00	-
Purchase of Investments	-232	-301	-416
Sale and/or Maturity of Investments	344	394	179
Net Cash From Financing Activities	0.35	3.54	432
Net Cash From Continuing Financing Activities	0.35	3.54	432
Other Financing Activities, net	0.35	3.54	231
Effect of Exchange Rate Changes	-0.44	0.16	-0.07
Cash Income Taxes Paid	0.71	6.39	0.03

This table details how cash moves in and out of Amylyx Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	5.56	-2.44	-96	0.35	35	-113	133	52	-45	41
Net Cash From Operating Activities	-59	-42	-67	-0.49	14	-5.17	8.61	-5.07	-50	-43
Net Cash From Continuing Operating Activities	-59	-42	-67	-0.49	14	-5.17	8.61	-5.07	-50	-43
Net Income / (Loss) Continuing Operations	-38	-73	-73	-119	4.73	21	22	1.57	-43	-54
Consolidated Net Income / (Loss)	-38	-73	-73	-119	4.73	21	22	1.57	-43	-54
Depreciation Expense	0.16	0.22	0.21	0.32	0.30	0.30	0.28	0.20	0.18	0.17
Amortization Expense	-1.79	-2.31	-3.18	-2.58	-2.57	-2.48	-1.98	-2.90	-1.86	-0.09
Non-Cash Adjustments To Reconcile Net Income	5.42	44	18	121	8.20	11	10	7.94	6.54	6.14
Changes in Operating Assets and Liabilities, net	-25	-11	-9.18	-0.31	2.89	-35	-22	-12	-12	4.66
Net Cash From Investing Activities	65	39	-29	0.82	21	-108	123	56	-228	84
Net Cash From Continuing Investing Activities	65	39	-29	0.82	21	-108	123	56	-228	84
Purchase of Property, Plant & Equipment	-0.02	0.02	-0.09	-0.07	-0.36	-0.36	-0.28	-0.25	-0.62	-0.46
Sale and/or Maturity of Investments	65	75	130	74	148	57	124	66	34	85
Net Cash From Financing Activities	0.11	0.08	0.03	0.13	0.23	0.89	1.38	1.04	232	-
Net Cash From Continuing Financing Activities	0.11	0.08	0.03	0.13	0.23	0.89	1.38	1.04	232	-1.52
Other Financing Activities, net	0.11	0.08	0.03	0.13	0.23	0.89	1.38	1.04	232	-1.52
Effect of Exchange Rate Changes	-0.53	0.24	-0.04	-0.11	0.24	-0.13	-0.02	0.08	0.51	-0.37
Cash Income Taxes Paid	0.97	0.02	-0.01	-0.28	11	-2.42	-2.56	0.00	0.05	-0.03

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	194	517	391
Total Current Assets	189	465	382
Cash & Equivalents	77	170	63
Short-Term Investments	99	201	284
Accounts Receivable	0.45	40	15
Inventories, net	0.00	38	9.77
Prepaid Expenses	12	15	10
Plant, Property, & Equipment, net	0.96	2.69	2.61
Total Noncurrent Assets	3.24	50	6.71
Other Noncurrent Operating Assets	3.24	50	6.71
Total Liabilities & Shareholders' Equity	194	517	391
Total Liabilities	29	84	51
Total Current Liabilities	28	82	47
Accounts Payable	2.94	22	6.26
Accrued Expenses	24	58	38
Other Current Liabilities	1.52	2.26	2.04
Total Noncurrent Liabilities	0.46	1.98	4.24
Noncurrent Deferred Revenue	0.00	0.00	0.00
Other Noncurrent Operating Liabilities	0.46	1.98	4.24
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	165	433	341
Total Preferred & Common Equity	165	433	341
Preferred Stock	0.00	0.00	0.00
Total Common Equity	165	433	341
Common Stock	772	738	695
Retained Earnings	-607	-305	-354
Accumulated Other Comprehensive Income / (Loss)	-0.09	0.20	-0.09

This table presents Amylyx Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	251	332	417	467	454	408	181
Total Current Assets	245	327	411	434	427	389	172
Cash & Equivalents	72	75	171	135	248	115	108
Short-Term Investments	163	235	203	220	110	231	55
Accounts Receivable	1.73	4.09	20	29	33	18	0.14
Inventories, net	0.00	0.00	0.00	32	25	13	0.56
Prepaid Expenses	9.14	13	17	17	12	13	8.34
Plant, Property, & Equipment, net	1.25	1.47	2.46	2.76	2.64	2.56	2.12
Total Noncurrent Assets	4.20	3.97	4.46	30	24	16	7.13
Other Noncurrent Operating Assets	4.20	3.97	4.46	30	24	16	7.13
Total Liabilities & Shareholders' Equity	251	332	417	467	454	408	181
Total Liabilities	55	71	93	48	67	55	37
Total Current Liabilities	54	70	92	46	64	52	33
Accounts Payable	1.49	4.96	21	6.37	25	11	7.05
Accrued Expenses	50	63	68	37	37	39	24
Other Current Liabilities	1.97	2.37	2.31	2.20	2.15	2.09	1.99
Total Noncurrent Liabilities	0.60	0.77	1.38	2.57	3.14	3.69	4.77
Other Noncurrent Operating Liabilities	0.60	0.77	1.38	2.57	3.14	3.69	4.77
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	196	261	324	418	386	353	144
Total Preferred & Common Equity	196	261	324	418	386	353	144
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	196	261	324	418	386	353	144
Common Stock	765	758	748	728	717	705	456
Retained Earnings	-569	-496	-424	-310	-331	-353	-312
Accumulated Other Comprehensive Income / (Loss)	0.64	-0.10	-0.08	-0.15	-0.07	0.03	-0.73

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-77.06%	1,612.94%	7,700.00%
EBITDA Growth	-1,209.24%	114.40%	-131.75%
EBIT Growth	-928.34%	118.89%	-129.51%
NOPAT Growth	-725.70%	124.98%	-143.49%
Net Income Growth	-712.42%	124.84%	-125.60%
EPS Growth	-732.86%	120.65%	74.61%
Operating Cash Flow Growth	-1,506.55%	106.63%	-140.47%
Free Cash Flow Firm Growth	-341.31%	76.71%	0.00%
Invested Capital Growth	-118.91%	1,079.33%	20.13%
Revenue Q/Q Growth	-55.53%	29.42%	6,343.48%
EBITDA Q/Q Growth	-14.83%	267.33%	-6.32%
EBIT Q/Q Growth	-15.59%	512.57%	-5.37%
NOPAT Q/Q Growth	-15.65%	1,514.06%	-8.80%
Net Income Q/Q Growth	-16.29%	2,583.61%	-7.80%
EPS Q/Q Growth	-15.97%	3,400.00%	51.36%
Operating Cash Flow Q/Q Growth	-76.31%	123.22%	-13.54%
Free Cash Flow Firm Q/Q Growth	-64.70%	60.67%	0.00%
Invested Capital Q/Q Growth	69.27%	-2.03%	65.86%
Profitability Metrics	-	-	-
Gross Margin	93.19%	93.32%	86.54%
EBITDA Margin	-371.86%	7.69%	-915.25%
Operating Margin	-360.22%	10.19%	-905.72%
EBIT Margin	-361.61%	10.02%	-908.20%
Profit (Net Income) Margin	-345.36%	12.94%	-892.38%
Tax Burden Percent	99.87%	90.74%	100.39%
Interest Burden Percent	95.63%	142.35%	97.87%
Effective Tax Rate	0.00%	9.26%	0.00%
Return on Invested Capital (ROIC)	-875.40%	126.36%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-845.67%	122.44%	0.00%
Return on Net Nonoperating Assets (RNNOA)	774.52%	-113.62%	0.00%
Return on Equity (ROE)	-100.88%	12.73%	-92.53%
Cash Return on Invested Capital (CROIC)	0.00%	-53.48%	0.00%
Operating Return on Assets (OROA)	-88.86%	8.39%	-81.23%
Return on Assets (ROA)	-84.87%	10.84%	-79.82%
Return on Common Equity (ROCE)	-100.88%	12.73%	-40.88%
Return on Equity Simple (ROE_SIMPLE)	-183.14%	11.37%	-58.24%
Net Operating Profit after Tax (NOPAT)	-220	35	-141
NOPAT Margin	-252.16%	9.25%	-634.00%
Net Nonoperating Expense Percent (NNEP)	-29.73%	3.92%	-25.93%
Return On Investment Capital (ROIC_SIMPLE)	-133.71%	8.12%	-
Cost of Revenue to Revenue	6.81%	6.68%	13.46%
SG&A Expenses to Revenue	130.86%	49.47%	571.88%
R&D to Revenue	160.56%	33.66%	420.38%
Operating Expenses to Revenue	453.41%	83.13%	992.25%
Earnings before Interest and Taxes (EBIT)	-316	38	-202
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-325	29	-203
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.57	2.29	7.19
Price to Tangible Book Value (P/TBV)	1.57	2.29	7.19
Price to Revenue (P/Rev)	2.97	2.61	110.13
Price to Earnings (P/E)	0.00	20.17	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	4.96%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	10.03	0.00
Enterprise Value to Revenue (EV/Rev)	0.95	1.63	94.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	21.25	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	16.32	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	17.68	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	52.23	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.92	-0.93	-1.03
Leverage Ratio	1.19	1.17	1.16
Compound Leverage Factor	1.14	1.67	1.13
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-2.94	8.14	27.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	55.82%
Liquidity Ratios	-	-	-
Current Ratio	6.67	5.66	8.20
Quick Ratio	6.23	5.01	7.77
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-147	-33	-143
Operating Cash Flow to CapEx	-106,781.53%	960.44%	-7,120.78%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.25	0.84	0.09
Accounts Receivable Turnover	4.31	13.76	0.00
Inventory Turnover	0.00	1.06	0.00
Fixed Asset Turnover	47.91	143.77	14.41
Accounts Payable Turnover	0.48	1.80	0.56
Days Sales Outstanding (DSO)	84.59	26.53	0.00
Days Inventory Outstanding (DIO)	0.00	344.99	0.00
Days Payable Outstanding (DPO)	766.42	203.14	648.11
Cash Conversion Cycle (CCC)	-681.83	168.38	-648.11
Capital & Investment Metrics	-	-	-
Invested Capital	-12	62	-6.34
Invested Capital Turnover	3.47	13.66	-3.12
Increase / (Decrease) in Invested Capital	-74	68	1.60
Enterprise Value (EV)	83	622	2,101
Market Capitalization	259	994	2,448
Book Value per Share	$2.40	$6.42	$5.14
Tangible Book Value per Share	$2.40	$6.42	$5.14
Total Capital	165	433	341
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-177	-371	-347
Capital Expenditures (CapEx)	0.16	1.24	2.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	11	-11
Debt-free Net Working Capital (DFNWC)	161	383	336
Net Working Capital (NWC)	161	383	336
Net Nonoperating Expense (NNE)	81	-14	57
Net Nonoperating Obligations (NNO)	-177	-371	-347
Total Depreciation and Amortization (D&A)	-8.95	-8.85	-1.57
Debt-free, Cash-free Net Working Capital to Revenue	-17.71%	2.96%	-51.38%
Debt-free Net Working Capital to Revenue	184.30%	100.48%	1,509.33%
Net Working Capital to Revenue	184.30%	100.48%	1,509.33%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($4.43)	$0.73	($3.39)
Adjusted Weighted Average Basic Shares Outstanding	68.14M	67.23M	58.50M
Adjusted Diluted Earnings per Share	($4.43)	$0.70	($3.39)
Adjusted Weighted Average Diluted Shares Outstanding	68.14M	69.99M	58.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.60M	67.78M	66.72M
Normalized Net Operating Profit after Tax (NOPAT)	-204	35	-141
Normalized NOPAT Margin	-233.85%	9.25%	-634.00%
Pre Tax Income Margin	-345.81%	14.26%	-888.89%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Amylyx Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.61%	-99.59%	-101.04%	24.10%	395.54%	29,666.09%	0.00%	0.00%	0.00%	21.05%
EBITDA Growth	-25,278.31%	-585.21%	-532.94%	-2,395.89%	99.65%	129.50%	133.92%	89.51%	-34.66%	-135.40%
EBIT Growth	-2,023.85%	-515.76%	-481.56%	-5,207.86%	104.65%	133.46%	137.06%	95.16%	-29.40%	-135.39%
NOPAT Growth	-2,114.18%	-403.48%	-387.49%	-3,614.16%	104.53%	145.59%	148.91%	93.12%	-57.49%	-138.59%
Net Income Growth	-893.62%	-447.98%	-429.35%	-7,652.00%	111.08%	138.87%	140.83%	103.29%	-50.66%	-132.29%
EPS Growth	-871.43%	-456.67%	-445.16%	-8,850.00%	111.48%	132.61%	133.33%	102.15%	85.44%	73.10%
Operating Cash Flow Growth	-535.45%	-704.22%	-873.38%	90.36%	127.27%	88.00%	118.53%	87.52%	-75.96%	-106.46%
Free Cash Flow Firm Growth	167.69%	175.36%	199.12%	-26.03%	-104.18%	-227.05%	-1.33%	-22.51%	0.00%	0.00%
Invested Capital Growth	-118.91%	-160.28%	-266.74%	-800.56%	1,079.33%	441.26%	309.39%	148.91%	20.13%	0.00%
Revenue Q/Q Growth	-259.86%	140.66%	-101.15%	-18.26%	5.61%	4.56%	37.50%	226.38%	6,243.48%	0.00%
EBITDA Q/Q Growth	45.91%	2.32%	36.28%	-75,287.95%	-101.03%	-12.85%	467.33%	89.32%	13.69%	-0.20%
EBIT Q/Q Growth	46.58%	1.26%	37.52%	-5,937.39%	-88.45%	-9.38%	969.11%	94.89%	16.89%	-0.34%
NOPAT Q/Q Growth	46.27%	0.82%	37.54%	-6,150.87%	-91.90%	-6.04%	906.97%	92.63%	18.45%	-0.79%
Net Income Q/Q Growth	48.36%	-0.01%	38.80%	-2,610.95%	-77.36%	-5.35%	1,303.31%	103.68%	20.56%	0.58%
EPS Q/Q Growth	49.53%	0.00%	38.86%	-2,600.00%	-76.67%	-3.23%	1,450.00%	103.28%	33.70%	1.08%
Operating Cash Flow Q/Q Growth	-41.95%	37.56%	-13,515.54%	-103.61%	362.16%	-160.04%	269.74%	89.79%	-15.37%	7.28%
Free Cash Flow Firm Q/Q Growth	-6.66%	100.83%	181.56%	55.73%	-3.92%	-164.14%	-3.70%	28.27%	-66.46%	18.16%
Invested Capital Q/Q Growth	69.27%	21.26%	0.72%	-178.71%	-2.03%	117.80%	317.11%	210.03%	65.86%	-33.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	0.00%	93.29%	91.37%	94.92%	94.32%	92.60%	87.11%	50.14%
EBITDA Margin	0.00%	-18,722.60%	0.00%	-141.18%	-0.15%	15.63%	18.75%	-7.02%	-214.58%	-15,769.86%
Operating Margin	0.00%	-18,187.74%	0.00%	-137.78%	1.78%	18.23%	20.57%	-2.87%	-203.76%	-15,849.57%
EBIT Margin	0.00%	-18,221.63%	0.00%	-138.62%	1.94%	17.75%	20.49%	-3.24%	-206.91%	-15,791.88%
Profit (Net Income) Margin	0.00%	-17,476.92%	0.00%	-134.01%	4.36%	20.35%	22.48%	2.20%	-195.13%	-15,581.45%
Tax Burden Percent	98.34%	100.00%	100.00%	100.20%	73.05%	93.23%	91.95%	112.12%	101.37%	99.77%
Interest Burden Percent	94.28%	95.91%	94.70%	96.48%	307.65%	122.92%	119.32%	-60.60%	93.03%	98.90%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	26.95%	6.77%	8.05%	-12.12%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-198,826.27%	0.00%	0.00%	17.80%	223.27%	477.55%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-198,819.57%	0.00%	0.00%	16.88%	221.94%	476.31%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	190,679.53%	0.00%	0.00%	-15.66%	-204.27%	-463.81%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-8,146.74%	-51.22%	-21.00%	2.14%	19.00%	13.74%	-50.19%	-92.53%	-127.76%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-53.48%	-133.23%	-342.98%	-1,866.06%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-9,982.69%	0.00%	-133.68%	1.63%	16.12%	11.58%	-0.89%	-18.51%	-30.03%
Return on Assets (ROA)	0.00%	-9,574.70%	0.00%	-129.24%	3.66%	18.47%	12.71%	0.60%	-17.45%	-29.63%
Return on Common Equity (ROCE)	0.00%	-8,146.74%	-51.22%	-21.00%	2.14%	19.00%	13.74%	-50.19%	-40.88%	-127.76%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-132.24%	-63.48%	-21.91%	0.00%	0.44%	-18.85%	-42.24%	0.00%	-127.76%
Net Operating Profit after Tax (NOPAT)	-28	-53	-53	-85	1.41	17	19	-2.30	-31	-38
NOPAT Margin	0.00%	-12,731.42%	0.00%	-96.44%	1.30%	16.99%	18.91%	-3.22%	-142.63%	-11,094.70%
Net Nonoperating Expense Percent (NNEP)	-3.32%	-6.70%	-5.79%	-9.26%	0.92%	1.33%	1.24%	1.29%	-5.19%	-19.04%
Return On Investment Capital (ROIC_SIMPLE)	-17.27%	-	-	-	0.33%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	6.71%	8.63%	5.08%	5.68%	7.40%	12.89%	49.86%
SG&A Expenses to Revenue	0.00%	4,285.58%	0.00%	65.16%	48.17%	47.44%	44.18%	61.61%	186.63%	8,678.26%
R&D to Revenue	0.00%	13,807.69%	0.00%	41.30%	41.41%	29.25%	29.57%	33.87%	104.24%	7,221.45%
Operating Expenses to Revenue	0.00%	18,287.74%	0.00%	231.07%	89.59%	76.69%	73.75%	95.48%	290.87%	15,899.71%
Earnings before Interest and Taxes (EBIT)	-40	-76	-77	-123	2.11	18	20	-2.32	-45	-54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-78	-80	-125	-0.17	16	18	-5.01	-47	-54
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.57	1.12	0.49	0.59	2.29	2.95	3.75	5.55	7.19	11.44
Price to Tangible Book Value (P/TBV)	1.57	1.12	0.49	0.59	2.29	2.95	3.75	5.55	7.19	11.44
Price to Revenue (P/Rev)	2.97	1.12	0.43	0.48	2.61	4.19	7.55	20.90	110.13	4,775.97
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	20.17	671.94	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	4.96%	0.15%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	10.03	13.87	37.53	231.11	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.95	0.00	0.00	0.00	1.63	2.99	5.69	17.21	94.52	4,304.69
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	21.25	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	16.32	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	17.68	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	52.23	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.92	-0.96	-1.03	-1.06	-0.93	-0.92	-0.97	-1.01	-1.03	-1.13
Leverage Ratio	1.19	1.17	1.21	1.22	1.17	1.15	1.17	1.15	1.16	1.26
Compound Leverage Factor	1.12	1.12	1.15	1.18	3.61	1.42	1.40	-0.70	1.08	1.25
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.76	-0.05	0.07	0.71	7.91	16.19	13.44	21.23	28.33	23.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	55.82%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.67	4.55	4.66	4.48	5.66	9.52	6.67	7.54	8.20	5.27
Quick Ratio	6.23	4.38	4.48	4.30	5.01	8.43	6.10	7.04	7.77	4.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	45	49	24	-30	-67	-64	-24	-24	-33	-20
Operating Cash Flow to CapEx	-295,040.00%	0.00%	-74,808.99%	-729.85%	3,806.46%	-1,447.90%	3,096.76%	-2,028.80%	-8,015.65%	-9,385.19%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.25	0.55	0.76	0.96	0.84	0.91	0.57	0.27	0.09	0.00
Accounts Receivable Turnover	4.31	12.64	15.91	21.00	13.76	19.95	0.00	0.00	0.00	2.52
Inventory Turnover	0.00	0.00	0.00	0.00	1.06	1.15	0.00	0.00	0.00	0.31
Fixed Asset Turnover	47.91	97.92	145.38	158.63	143.77	120.61	85.39	48.67	14.41	0.16
Accounts Payable Turnover	0.48	3.90	1.38	1.62	1.80	2.82	0.84	0.80	0.56	0.02
Days Sales Outstanding (DSO)	84.59	28.87	22.95	17.38	26.53	18.29	0.00	0.00	0.00	144.94
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	344.99	318.01	0.00	0.00	0.00	1,194.74
Days Payable Outstanding (DPO)	766.42	93.65	263.56	225.29	203.14	129.60	432.17	459.01	648.11	14,965.00
Cash Conversion Cycle (CCC)	-681.83	-64.78	-240.61	-207.91	168.38	206.70	-432.17	-459.01	-648.11	-13,625.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-12	-38	-49	-49	62	63	29	6.97	-6.34	-19
Invested Capital Turnover	3.47	15.62	-30.78	-19.01	13.66	13.14	25.25	-25.71	-3.12	-0.04
Increase / (Decrease) in Invested Capital	-74	-102	-78	-56	68	82	43	21	1.60	-19
Enterprise Value (EV)	83	-14	-181	-182	622	879	1,092	1,612	2,101	1,485
Market Capitalization	259	221	129	192	994	1,234	1,449	1,957	2,448	1,648
Book Value per Share	$2.40	$2.88	$3.84	$4.78	$6.42	$6.21	$5.75	$5.29	$5.14	$2.46
Tangible Book Value per Share	$2.40	$2.88	$3.84	$4.78	$6.42	$6.21	$5.75	$5.29	$5.14	$2.46
Total Capital	165	196	261	324	433	418	386	353	341	144
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-177	-234	-310	-373	-371	-355	-357	-346	-347	-163
Capital Expenditures (CapEx)	0.02	-0.02	0.09	0.07	0.36	0.36	0.28	0.25	0.62	0.46
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-43	-53	-54	11	33	6.04	-8.24	-11	-23
Debt-free Net Working Capital (DFNWC)	161	191	257	319	383	388	363	337	336	140
Net Working Capital (NWC)	161	191	257	319	383	388	363	337	336	140
Net Nonoperating Expense (NNE)	9.09	20	19	33	-3.32	-3.44	-3.50	-3.87	11	15
Net Nonoperating Obligations (NNO)	-177	-234	-310	-373	-371	-355	-357	-346	-347	-163
Total Depreciation and Amortization (D&A)	-1.63	-2.08	-2.97	-2.27	-2.27	-2.18	-1.70	-2.70	-1.68	0.08
Debt-free, Cash-free Net Working Capital to Revenue	-17.71%	-21.91%	-17.80%	-13.67%	2.96%	11.37%	3.15%	-8.79%	-51.38%	-6,678.55%
Debt-free Net Working Capital to Revenue	184.30%	97.39%	85.90%	80.12%	100.48%	132.04%	189.35%	360.29%	1,509.33%	40,449.86%
Net Working Capital to Revenue	184.30%	97.39%	85.90%	80.12%	100.48%	132.04%	189.35%	360.29%	1,509.33%	40,449.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.54)	($1.07)	($1.07)	($1.75)	$0.07	$0.31	$0.33	$0.02	($0.61)	($0.92)
Adjusted Weighted Average Basic Shares Outstanding	68.14M	68.09M	68.02M	67.85M	67.23M	67.41M	67.23M	66.72M	58.50M	58.53M
Adjusted Diluted Earnings per Share	($0.54)	($1.07)	($1.07)	($1.75)	$0.07	$0.30	$0.31	$0.02	($0.61)	($0.92)
Adjusted Weighted Average Diluted Shares Outstanding	68.14M	68.09M	68.02M	67.85M	69.99M	69.75M	70.13M	70.86M	58.50M	58.53M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.60M	68.55M	68.08M	68.01M	67.78M	67.52M	67.38M	67.18M	66.72M	66.26M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-53	-37	-85	1.41	17	19	-1.44	-31	-38
Normalized NOPAT Margin	0.00%	-12,731.42%	0.00%	-96.44%	1.30%	16.99%	18.91%	-2.01%	-142.63%	-11,094.70%
Pre Tax Income Margin	0.00%	-17,476.92%	0.00%	-133.74%	5.97%	21.82%	24.44%	1.96%	-192.48%	-15,617.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

When does Amylyx Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Amylyx Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Amylyx Pharmaceuticals' net income changed over the last 2 years?

Amylyx Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$301.74 million in 2024, rising from -$198.38 million in 2022. The previous period was $49.27 million in 2023. Find out what analysts predict for Amylyx Pharmaceuticals in the coming months.

What is Amylyx Pharmaceuticals's operating income?

Amylyx Pharmaceuticals's total operating income in 2024 was -$314.73 million, based on the following breakdown:

Total Gross Profit: $81.42 million
Total Operating Expenses: $396.15 million

How has Amylyx Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' total revenue changed from $22.23 million in 2022 to $87.37 million in 2024, a change of 293.0%.

How much debt does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals' total liabilities were at $28.87 million at the end of 2024, a 65.6% decrease from 2023, and a 43.2% decrease since 2022.

How much cash does Amylyx Pharmaceuticals have?

In the past 2 years, Amylyx Pharmaceuticals' cash and equivalents has ranged from $62.53 million in 2022 to $170.20 million in 2023, and is currently $77.39 million as of their latest financial filing in 2024.

How has Amylyx Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Amylyx Pharmaceuticals' book value per share changed from 5.14 in 2022 to 2.40 in 2024, a change of -53.2%.

Related Companies

This page (NASDAQ:AMLX) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Financials

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Financials

Annual Income Statements for Amylyx Pharmaceuticals

Quarterly Income Statements for Amylyx Pharmaceuticals

Annual Cash Flow Statements for Amylyx Pharmaceuticals

Quarterly Cash Flow Statements for Amylyx Pharmaceuticals

Annual Balance Sheets for Amylyx Pharmaceuticals

Quarterly Balance Sheets for Amylyx Pharmaceuticals

Annual Metrics And Ratios for Amylyx Pharmaceuticals

Quarterly Metrics And Ratios for Amylyx Pharmaceuticals

Frequently Asked Questions About Amylyx Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools